Why a weight-loss drug trial matters for knee pain
Knee osteoarthritis is one of the most common sources of chronic joint pain, and obesity is one of its strongest modifiable risk factors: excess body weight increases mechanical load on the knee and may also drive a low-grade inflammatory state that affects the joint. Weight loss is already part of standard osteoarthritis care alongside exercise and, when needed, anti-inflammatory medication. What has been less clear is whether the newer generation of injectable weight-loss drugs, developed for obesity and diabetes, meaningfully helps the joint pain itself, beyond whatever benefit comes from the pounds lost. A first answer for this drug class came in 2024, when a trial of semaglutide (sold as Wegovy for weight loss) found a significant knee pain benefit in people with obesity and osteoarthritis.[3] The trial covered here asks the same question about a newer, more potent, and still entirely investigational drug called retatrutide.
Inside TRIUMPH-4 and TRIUMPH-1-OA
Retatrutide is a triple-receptor agonist, meaning it activates three separate hormone receptors (GIP, GLP-1, and glucagon) rather than the one or two targeted by earlier drugs such as semaglutide or tirzepatide.[1] Two phase 3 trials, reported together in a single paper published in the New England Journal of Medicine on November 8, 2026, tested it specifically in people with obesity and painful, X-ray-confirmed knee osteoarthritis who did not have diabetes.[1] TRIUMPH-4 randomized 445 participants, in roughly equal groups, to weekly subcutaneous retatrutide at 9mg, 12mg, or placebo for 68 weeks.[1][4] TRIUMPH-1-OA, the knee-osteoarthritis arm of a larger master protocol, randomized 574 participants to 4mg, 9mg, 12mg, or placebo for 80 weeks.[1][5] Both trials capped female enrollment at roughly 70% to ensure adequate male representation, and about 80% of participants in each trial had a BMI above 35.[1] Both were funded by Eli Lilly, which manufactures retatrutide; several co-authors on the paper are Lilly employees.[1]
How much pain relief the trials found
Both trials used the WOMAC pain subscale, a standard 0-to-10 osteoarthritis pain measure where higher scores mean worse pain, as their key pain outcome.[1] In TRIUMPH-4 at 68 weeks, pain scores fell by a mean of 3.96 points on 9mg and 3.74 points on 12mg, versus 2.12 points on placebo, differences of roughly 1.6 to 1.8 points favoring retatrutide (95% CI for the 9mg difference, -2.37 to -1.30; P<0.001 for both doses).[1]In TRIUMPH-1-OA at 80 weeks, pain scores fell by 3.22 (4mg), 3.48 (9mg), and 3.64 points (12mg), versus 1.87 points on placebo, again significant at every dose (P≤0.005).[1] Pooling both trials, 63.2% to 69.6% of retatrutide-treated participants achieved a clinically meaningful 50% or greater reduction in pain by week 68, compared with 37.8% on placebo; for physical function, 63.5% to 64.6% reached that threshold versus 33.1% on placebo.[1]
The weight loss that came with it
The weight loss in both trials was substantial by any standard. In TRIUMPH-4, mean body weight fell by 20.0% on the 9mg dose and 23.7% on the 12mg dose, versus 4.6% on placebo (P<0.001 for both).[1] In TRIUMPH-1-OA, the corresponding figures were 17.5% (4mg), 22.9% (9mg), and 24.8% (12mg), versus 4.3% on placebo.[1] These numbers are consistent with the weight loss retatrutide produced in the larger TRIUMPH-1 obesity trial it was drawn from, which enrolled 2,339 participants overall and also reported improvements in triglycerides, blood pressure, and other cardiometabolic markers.[2] That consistency across a larger and a more targeted trial population is a reasonable basis for confidence in the weight-loss effect itself, even though the osteoarthritis-specific pain benefit is newer evidence from just these two trials.
How this compares with other knee OA treatments
The trial’s own authors put their pain result in context using Cohen’s d, a standardized measure of effect size that allows rough comparison across different studies and treatments. Retatrutide’s effect size on knee pain (0.55 to 0.79, across the two trials) was larger than effect sizes reported elsewhere for maximum-dose ibuprofen (0.37), maximum-dose tramadol (0.31), and roughly comparable to intra-articular glucocorticoid injections versus oral placebo (0.61).[1] It was also somewhat larger than the effect size the authors calculate for semaglutide versus placebo on the same pain measure (0.50), based on the 2024 STEP 9 trial.[1][3] In that earlier trial, semaglutide reduced WOMAC pain scores (measured on a 0-to-100 scale in that study) by 41.7 points versus 27.5 points on placebo over 68 weeks, with 13.7% weight loss versus 3.2% on placebo.[3] These are cross-study comparisons, not head-to-head trials of retatrutide against ibuprofen or semaglutide, so treat the ranking as suggestive rather than definitive.
A larger standardized effect size than max-dose ibuprofen is a meaningful signal. It is not the same as a trial that put these treatments head-to-head in the same patients.
Why a weight-loss drug might help a joint
The trial authors describe the mechanism as “incompletely understood.”[1] The leading explanation is mechanical: prior research cited in the paper suggests each pound of body weight lost reduces peak knee compressive force by roughly a four-to-one ratio, so substantial weight loss meaningfully unloads the joint with every step.[1] A second, more speculative possibility raised by the authors is that reducing excess adipose tissue lowers systemic inflammatory signaling in a way that could ease osteoarthritis pain somewhat independently of weight itself, though they are explicit that further study is needed to confirm this.[1]
Adverse events and who dropped out
Gastrointestinal side effects, mainly nausea, diarrhea, and constipation, were the most frequent adverse events in both trials, generally mild to moderate and concentrated during the dose-escalation period.[1] Serious adverse events were more common with retatrutide than placebo in both trials, and discontinuation due to adverse events ranged from roughly 3% to 18% across retatrutide doses, compared with 4% to 6% on placebo, rising at higher doses.[1] Two deaths occurred among retatrutide-treated participants in TRIUMPH-4 (one each at the 9mg and 12mg doses); investigators assessed both as unrelated to the study drug. No deaths occurred in TRIUMPH-1-OA.[1]
What these trials do not show
The authors list several specific limits on their own conclusions. The earliest pain and function assessment came at week 16, so how quickly the benefit starts is unknown. Inflammatory markers were measured only at the start and end of each trial, not in between, which limits what can be said about the inflammation hypothesis above. Most importantly, neither trial was designed to assess whether retatrutide slows the structural progression of osteoarthritis or reduces the eventual need for knee replacement, and both enrolled only participants with obesity, so the findings do not speak to osteoarthritis pain in people at a normal weight.[1]
Retatrutide is not an approved medication
It is worth being direct about this: retatrutide is not FDA-approved for knee osteoarthritis, weight loss, or anything else. It remains an investigational drug available only through clinical trials.[6] The FDA has stated that retatrutide is not a component of any approved drug, has not been found safe and effective for any condition, and cannot legally be used in compounding under federal law.[6]The agency has separately warned telehealth companies and online sellers marketing products labeled “retatrutide, ” including some sold as “for research purposes only” despite shipping with human dosing instructions, and urges consumers not to buy them because their actual contents and quality are unverified.[6] Our broader guide to approved GLP-1 medications covers the drugs in this general class that are actually prescribable today.
If you are considering a GLP-1-class medication for weight or joint pain
- Only semaglutide (Wegovy) and tirzepatide (Zepbound), among this drug family, currently carry FDA approval for chronic weight management.
- Do not buy any product labeled "retatrutide" from an online seller, telehealth site, or compounding pharmacy; it is not legally compoundable and its contents cannot be verified.
- If knee osteoarthritis and excess weight are both factors for you, discuss evidence-based options, including approved weight-loss medications, physical therapy, and weight management programs, with a clinician.
The bottom line
Two large, well-designed, industry-funded trials found that retatrutide, an investigational triple-hormone agonist, significantly reduced both knee osteoarthritis pain and body weight compared with placebo in adults with obesity, with an effect size on pain that compares favorably with some existing non-surgical treatments. That is a genuinely useful, specific result. It is not evidence that the drug slows joint damage, not evidence it works in people without obesity, and not a treatment anyone can actually be prescribed today, since retatrutide remains unapproved. See how we grade evidence strength across topics in our editorial and evidence standards.
Medical disclaimer
This article is for educational purposes only and does not constitute medical advice. It does not establish a doctor-patient relationship. Always consult a qualified clinician before starting, stopping, or changing any treatment for knee pain or weight management.
Frequently asked questions
Can I get a prescription for retatrutide for my knee pain right now?
No. Retatrutide is an investigational drug that has not been approved by the FDA for knee osteoarthritis, weight loss, or any other condition. It cannot legally be prescribed outside a clinical trial, and under federal law it cannot be compounded by pharmacies either. If a telehealth company or online seller is offering you "retatrutide," the FDA has specifically warned that these products are unapproved, of unknown quality, and sometimes labeled "for research purposes only" despite being sold with human dosing instructions.
Is this basically proof that weight-loss drugs cure knee arthritis?
No. Two well-designed trials found that retatrutide reduced knee pain scores and body weight significantly more than placebo over 68 to 80 weeks in adults with obesity and knee osteoarthritis. That is a real, specific finding, not a cure. The trials were not designed to show whether retatrutide slows the underlying joint damage or reduces the eventual need for knee replacement, and the authors say so directly. It also will not help knee pain in someone who is not overweight or obese, since that population was not studied here.
Is retatrutide just semaglutide (Wegovy) or tirzepatide (Zepbound) under a different name?
No, it is a different molecule, though in the same broader family of incretin-based drugs. Retatrutide is a triple agonist that targets GIP, GLP-1, and glucagon receptors, while semaglutide targets only the GLP-1 receptor and tirzepatide targets GIP and GLP-1. A separate, earlier trial (STEP 9) tested semaglutide specifically for knee osteoarthritis and also found a significant pain benefit, so retatrutide is not the first drug in this class studied for this purpose, but it is a distinct, still-unapproved compound with its own safety and effectiveness data.
Why would a weight-loss drug reduce joint pain?
The leading explanation is mechanical: losing body weight reduces the load the knee carries with every step, and prior research suggests each pound of weight lost reduces knee compressive force by roughly four pounds. Researchers also raise a second, less certain possibility: that reducing excess fat tissue lowers systemic inflammatory signals that may contribute to osteoarthritis pain independent of weight. The trial authors describe this second mechanism as incompletely understood and in need of further study, so treat it as a plausible hypothesis rather than an established fact.
How common were side effects, and how serious were they?
Gastrointestinal symptoms (nausea, diarrhea, constipation), mostly mild to moderate and clustered during dose increases, were the most common side effects in both trials. Serious adverse events and treatment discontinuation because of side effects were more frequent with retatrutide than with placebo, rising with dose: discontinuation due to adverse events ranged from roughly 3% to 18% across retatrutide doses, compared with 4% to 6% on placebo. Two deaths occurred among retatrutide-treated participants in the TRIUMPH-4 trial; investigators assessed both as unrelated to the study drug.
References
- Schnitzer TJ, Hunter DJ, Conaghan PG, Sharma AM, Pedersen SD, Chen K, Park SY, Makarova N, Giblin K, Forrester T; TRIUMPH-4 and TRIUMPH-1-OA Investigators. Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity. New England Journal of Medicine. 2026. View on PubMed
- Jastreboff AM, Kaplan LM, Davies MJ, Wilding JPH, Ahmad NN, Murray M, Du Y, Makarova N, Giblin K, Schloot NC, Wang Y; TRIUMPH-1 Investigators. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine, 395(18):1781-1793. 2026. View on PubMed
- Bliddal H, Bays H, Czernichow S, Uddén Hemmingsson J, Hjelmesæth J, Hoffmann Morville T, Koroleva A, Skov Neergaard J, Vélez Sánchez P, Wharton S, Wizert A, Kristensen LE; STEP 9 Study Group. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. New England Journal of Medicine, 391(17):1573-1583. 2024. View on PubMed
- Eli Lilly and Company; U.S. National Library of Medicine, ClinicalTrials.gov. A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 (Retatrutide) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: TRIUMPH-4 (NCT05931367). ClinicalTrials.gov trial registration. 2023-2026. View trial registration
- Eli Lilly and Company; U.S. National Library of Medicine, ClinicalTrials.gov. A Master Protocol to Investigate the Efficacy and Safety of LY3437943 (Retatrutide) Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: TRIUMPH-1 (NCT05929066). ClinicalTrials.gov trial registration. 2023-2026. View trial registration
- U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. FDA drug safety communication. 2026. View FDA statement

